Compound Mannitol Injection

15% mannitol; 5% glucose; 0.45% sodium chloride.

Used to reduce intracranial pressure, intraocular pressure, diuresis and prevent and treat renal failure.

Intravenous drip, 100mI-250mI each time, 1-4 times/day. In special cases, use it according to the condition.

(1) Water and electrolyte disorders are the most common; (2) Chills, fever, allergies, thirst; (3) Difficulty urinating; (4) Thrombophlebitis; (5) Extravasation can cause tissue edema and skin necrosis; (6) Dizziness and blurred vision; (7) Osmotic nephropathy.

1. It is contraindicated for patients with severe renal disease or renal insufficiency. 2. It is contraindicated for patients with obvious pulmonary edema or severe congestive heart failure. 3. It is contraindicated for patients with severe dehydration. 4. It is contraindicated for patients with active intracranial hemorrhage other than intracranial surgery. 5. It is contraindicated for patients in a highly sensitive state. 6. It is contraindicated for pregnant women.

Precautions during pregnancy and lactation: Contraindicated for use during pregnancy.

(1) It can increase the toxic effects of digitalis, which is related to hypokalemia; (2) It can increase the diuretic and intraocular pressure-lowering effects of diuretics and carbonic anhydrase inhibitors. The dose should be adjusted when used in combination with these drugs.

Keep sealed.

250ml: 37.5g mannitol, 12.5g anhydrous glucose and 1.125g sodium chloride.

Hunan Kangyuan Pharmaceutical Co., Ltd.

• Founded in:

  2000-09-11

• Address:

  No. 8, Kangping Road, Liuyang Economic and Technological Development Zone

• Tax NO.:

  91430181740629146E

• Registered Funds:

  65 million yuan

• Email:

  Log in to view